Overall, our study explored a novel anti-NET strategy for the first time by using an oncolytic bacteria-mediated delivery system in which the CCDC25 nucleic acid drug was used to target CCDC25, a key gene for tumor cell metastasis, and showed promising application in terms of both safety and the inhibition of tumor metastasis. Here, CCDC25 is linked to neoplasm.